Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib vs Teriflunomide in Relapsing Multiple Sclerosis
NCT05147220Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2021
- Primary completion
- Jul 2026
- Countries
- 34
01
Overview
Phase 3, randomised, double-blind trial of remibrutinib in multiple sclerosis (MS) (4 arms), sponsored by Novartis. Primary endpoint: Annualized Relapse Rate at 5 years. Started Dec 2021; status: active, not recruiting.
02
Drugs
remibrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05147220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05147220.